Exosomes are circulating nanovesicular carriers of macromolecules, increasingly used for diagnostics and therapeutics. The ability to load and target patient-derived exosomes without altering exosomal surfaces is key to unlocking their therapeutic potential. We demonstrate that a peptide (CP05) identified by phage display enables targeting, cargo loading, and capture of exosomes from diverse origins, including patient-derived exosomes, through binding to CD63-an exosomal surface protein. Systemic administration of exosomes loaded with CP05-modified, dystrophin splice-correcting phosphorodiamidate morpholino oligomer (EXO PMO ) increased dystrophin protein 18-fold in quadriceps of dystrophin-deficient mdx mice compared to CP05-PMO. Loading CP05-muscletargeting peptide on EXO PMO further increased dystrophin expression in muscle with functional improvement without any detectable toxicity. Our study demonstrates that an exosomal anchor peptide enables direct, effective functionalization and capture of exosomes, thus providing a tool for exosome engineering, probing gene function in vivo, and targeted therapeutic drug delivery.
INTRODUCTION
Exosomes are nanoscale vesicles with sizes of 30 to 150 nm (in diameter) that are secreted by most mammalian cells and thus bear many macromolecules from their parental cells (1, 2) . These unique features enable exosomes to be used as diagnostic markers for pregnancy and various malignancies (3, 4) and also harnessed as delivery vehicles for a large variety of cargoes ranging from anticancer chemotherapeutics to nucleic acids (5) (6) (7) (8) . To avoid triggering an immune response, therapeutic exosomes should ideally be patient-derived, and subsequent modifications should not substantially affect the structure or surface of exosomes. Current methods of targeting exosomes with therapeutic macromolecules typically involve genetic manipulation of their producer cells or chemical conjugation of peptides to exosomal surface (9) . Genetic engineering of parental cells is labor-intensive with variable efficacy, depending on the transfection efficiency and cell types, and precludes the use of a patient's circulating exosomes for therapeutic use, whereas chemical functionalization of native exosomes, such as with click chemistry (9) , can largely alter surface structure. Transferrin had been used to paint patient-derived exosomes with paramagnetic particles (10) , but transferrin binds weakly to exosomes and is promiscuous because transferrin-binding molecules are abundant in blood. Electroporation (7), lyoph ilization, or transfection of parental cells (11, 12) can load exosomes with macromolecules, but these methods suffer from low loading efficiencies (13) .
To overcome these limitations, we used phage display to identify peptides that can anchor cargo and targeting moieties to exosomes. These peptides will greatly simplify the process of loading and functionalizing exosomes. Because genetic modification of producer cells is not required, patient-derived exosomes can be used.
CD63 is a tetraspanin enriched on the surface of exosomes and regarded as an exosomal marker (14) . We selected for peptides that specifically bind to the second extracellular loop of CD63 and characterized three candidate peptides in CD63-expressing cells and exosomes. One peptide in particular, CP05, enabled direct painting of exosomes with different moieties irrespective of the origin of exosomes.
Efficient delivery of functional cargoes in vivo is well recognized as one of the biggest challenges in therapeutic gene delivery and in disease modeling. In particular, insufficient systemic delivery of antisense oligonucleotides (AOs) for Duchenne muscular dystrophy (DMD) exon-skipping therapy hinders translation to the clinic (15) . Here, we painted exosomes, recovered by high-speed ultracentrifugation and 0.22-m diafiltration, with a phosphorodiamidate morpholino oligomer (PMO) (16) , currently approved by the U.S. Food and Drug Administration for treating DMD, as a CP05 conjugate, and demonstrated an 18-fold increase of dystrophin expression in quadriceps compared to naked PMO or the CP05-PMO conjugate without exosomes. CP05 also allows for simultaneous functionalization of exosomes with different moieties, including targeted PMO delivery to muscle in mdx mice by anchoring a muscle-targeting peptide and PMO on the same exosome with CP05. CP05 can anchor moieties not only to culture-derived exosomes from different cells but also to circulating exosomes from human serum. Furthermore, immobilized CP05 can also specifically capture exosomes from patients' serum. This study demonstrates that a CD63-specific exosomal anchor peptide enables direct and effective modification, cargo loading, and capture of exosomes and thus opens a new avenue for exosome engineering.
are specific for CD63 on exosomes, exosomes were incubated with His-tagged CP05-coated, a scrambled CP05-coated (table S1), or CP07-coated beads and lysed with protein lysis buffer. Proteins not directly bound to the beads were then washed off, and bound proteins were analyzed with Western blot. A stronger CD63 band was produced in the CP05 sample than CP07 (Fig. 1E) , suggesting that CP05 specifically binds CD63 with stronger affinity than CP07, whereas nothing bound to the scrambled CP05. Strikingly, there was no specific interaction with other tetraspanins such as CD81 and CD9 or other exosomal markers including Alix and Tsg101 detected for either CP05 or CP07. A similar experiment using CD63-expressing C2C12 cell lysates verified that CP05 specifically interacts with CD63 ( fig. S2D ). These findings support the conclusion that CP05 binds to exosomes through CD63 specifically.
CP05 does not alter characteristics and in vivo distribution of exosomes
Morphology and size distribution of exosomes were largely unchanged upon CP05 modification (Fig. 2, A and B) . To assess the modification showing the binding of rhodamine-labeled candidate peptides to murine myotube-derived exosomes. EXO CP0X (R) refers to the bead-bound filtrated peptide-exosome complex retentates. CP0X(R) refers to the bead-bound filtrated rhodamine-labeled peptide retentates and was used as a negative control. CP0X(UF) represents the bead-bound unfiltrated rhodamina-labeled peptide and was used as a positive control. (D) Flow cytometry for bead-bound rhodamine-labeled peptide-exosome complexes (n = 6). NC refers to beads alone. CP0X represents different peptides. (E) Western blot results for examining the specific binding affinity of candidate peptides to murine myotube-derived exosomes via CD63. EXO refers to exosomes; Scr-H6 refers to His-tagged scrambled CP05 peptide. All exosome lysates captured by His-tagged peptides were loaded for protein assay.
efficiency, the percentage of exosomes painted with at least one copy of CP05, we first examined whether flow cytometry can distinguish single exosome in the absence of beads (21) . A complete gate strategy for flow cytometry assay was established with beads of different sizes or buffers as positive or negative controls ( fig. S3A) (20 g) and DiR-labeled (5 g) exosomes were used. (D) Live animal imaging to examine the biodistribution of DiR-labeled EXO and EXO CP05 in wild-type C57BL/6 mice. Animals were imaged with IVIS spectrum at different time points after a single intravenous injection of 30 g of DiR-labeled EXO CP05 and EXO. DiR (0.3 g) and AF680-labeled CP05 (10 g) were used as controls. (E) Measurement of serum stability of CP05 with LC-MS. Peptide or peptide fragments were assayed at different time points including 0, 30, 60, 120, and 360 min after incubation with 20% serum at 37°C. one exosome; conversely, if multiple exosomes were found per drop, then this would likely register as a double positive. Two separate populations were observed when Pkh67-and DiR-labeled exosomes were mixed ( fig. S3B ), demonstrating that flow cytometry can be used to characterize individual exosomes. About 88.7% of DiR-labeled exosomes were modified with rhodamine-labeled CP05, as demonstrated by flow cytometry (Fig. 2C) , which is consistent with the abundance of CD63 expression on DiR-labeled exosomes ( fig. S3C ). Tissue distribution of DiR-labeled exosomes after intravenous administration in C57BL/6 mice was largely unaltered by CP05 modification when visualized with a small-animal imaging system (IVIS) in a real-time manner. Exosomes and EXO CP05 (CP05-modified exosomes) M12 versus EXO in quadriceps (*P = 0.0049), gastrocnemius (*P = 0.0024), and triceps (*P = 0.0135). Exosome were derived from human serum. Pkh67-labeled exosomes were used. Significance was determined by two-tailed t test (n = 3).
were mainly present in the liver at different time points, and no evident redistribution was found up to 48 hours after injection (Fig. 2D ). CP05 anchored on exosomes was still detectable at 4 hours after injection, whereas Alexa Fluor 680 (AF680)-labeled CP05 alone had disappeared by 2 hours after injection, indicating the ability of exosomes to protect CP05 from degradation. CP05 was incubated in 20% serum, and peptide integrity was measured at different time points with liquid chromatography-mass spectrometry (LC-MS) to establish serum stability. About 77% of the peptide remained intact after 6 hours, although trace degradation appeared after 30 min (Fig. 2E ). These findings demonstrate that CP05 modification does not alter the morphology, size, and tissue distribution of exosomes, and CP05 is relatively stable in blood after systemic administration. 3F ) and can be targeted to muscle in immunodeficient nude mice (Fig. 3G ). These findings demonstrate that CP05 is capable of painting CD63-positive exosomes efficiently at the peptide/exosome ratios attempted irrespective of origins of the exosomes.
CP05 can isolate exosomes from human serum
Because CP05 showed a strong and specific binding affinity to exosomes through CD63, we next investigated whether CP05 can be used to capture exosomes from human serum. An appreciable amount of circulating exosomes was captured from human serum with His-tagged CP05 on nickel Dynabeads (108.98 ± 7.82 g per milliliter of serum), which is about 54% of the amount captured via ultracentrifugation (200 g/ml of serum), indicated by the expression of exosomal marker protein (Fig. 4A ). Exosomes captured with CP05 showed the same typical sauce-cup shape and were within the same size range as those isolated from ultracentrifugation (Fig. 4 , B and C). To assess the utility of exosomes captured through CP05, we isolated exosomes from serum from patients with HCC and pancreatic cancer and examined the expression of tumor-associated antigens such as -fetoprotein (AFP; HCC-specific antigen) (24) and glypican-1 (GPC1; pancreatic cancer-specific antigen) (25) . Abundant AFP or GPC1 protein was detected in exosomes captured via CP05 from HCC or pancreatic
Number relative cancer patients' serum ( Fig. 4D) , indicating the ability of CP05 to isolate exosomes effectively.
CP05 allows dual modification of exosomes
Given the abundance of CD63 on exosomes (26), more than one moiety could possibly be anchored on exosomes. Rhodamine-labeled M12-CP05 and fluorescein isothiocyanate (FITC)-labeled NP41-CP05, a nerve-specific peptide (27) , were incubated with exosomes individually or together for 2 hours and followed by diafiltration to remove unbound peptides. Unsurprisingly, most exosomes were simultaneously labeled with both peptides (Fig. 5A) , suggesting that CP05 can anchor two different moieties on exosomes. We performed fluorescence resonance energy transfer (FRET) assay to ascertain the proximity of peptides present on the same exosome. As expected, stronger FRET signals were detected in exosomes modified with NP41-CP05 and RVG-CP05 than when single-labeled EXO NP41 and EXO RVG were mixed (Fig. 5B) , demonstrating that CP05 can modify individual exosomes with different moieties and the interaction is stable because the peptides are not jumping between EXO NP41 and EXO RVG .
CP05 directs efficient PMO loading on exosomes
We wondered whether CP05 could anchor therapeutic cargoes on exosomes to enhance delivery in vivo and thus used a PMO targeting the boundary of exons 22 and 23 in murine Dmd gene (16) and triceps (P = 0.0396) ( fig. S6 ). These data indicate that CP05-mediated anchoring PMO on exosomes can enhance PMO delivery in mdx mice.
CP05 enables targeted delivery of PMO to muscle
M12-CP05 and CP05-PMO were co-incubated with exosomes and injected into mdx mice intravenously at 12.5 mg of PMO per kilogram per week for 3 weeks. The combination of muscle-targeting peptide, PMO, and exosome (EXO PMO&M12 ) significantly enhanced the number of dystrophin-positive myofibers in quadriceps (P = 0.0054), gastrocnemius (P = 0.0018), and triceps (P = 0.0455) from treated mdx mice compared to EXO PMO under identical conditions, although no enhancement was observed in the heart (Fig. 7A) . Consistently, PMO and CP05-PMO in tibialis anterior (*P = 0.046), quadriceps (*P = 0.006), gastrocnemius (*P = 0.019), and triceps (*P = 0.033). Significance was determined by two-tailed t test (n = 4, mean ± SEM).
significantly higher efficiency of exon skipping (Fig. 7B ) and expression of dystrophin (Fig. 7C) were achieved in peripheral muscles treated with EXO PMO&M12 compared to EXO PMO , indicating that CP05 enabled targeted efficient delivery of PMO to muscle.
Pathological improvement was dem onstrated by relocalization of dystrophin-associated protein complex (DAPC) components (28) , which fail to localize to the sarcolemma in the absence of dys trophin, in EXO PMO&M12 -and EXO PMO -treated samples (Fig. 7D) . Functional (E) Muscle functional assessment to determine physical improvement over time in C57BL/6 normal controls, untreated mdx controls, and mdx mice treated with EXO PMO or EXO PMO&M12 . (F) Measurement of serum CK as an index of ongoing muscle membrane instability in C57BL/6 normal controls, untreated mdx controls, and mdx mice treated with CP05-PMO, EXO PMO , or EXO PMO&M12 : EXO PMO versus CP05-PMO (*P = 0.0024), EXO PMO&M12 versus CP05-PMO (*P = 0.0001), and EXO PMO&M12 versus EXO PMO (*P = 0.0083). Significance was determined by two-tailed t test (n = 4, mean ± SEM).
rescue was evident from force recovery in the grip strength test, with significant improvement in mdx mice treated with EXO PMO&M12 and EXO PMO , compared with CP05-PMO, PMO, and mdx controls (P = 0.0033) (Fig. 7E) , indicating that EXO PMO&M12 and EXO PMO elicit functional rescue in mdx mice. Analysis of serum biochemical indices, including serum creatine kinase (CK) (P < 0.005) (Fig. 7F) (29) , usually elevated in mdx mice; aspartate aminotransferase (AST) (P < 0.01) (Fig. 8A) and alanine aminotransferase (ALT) (P < 0.05) (Fig. 8A) showed significant decreases in mdx mice treated with EXO PMO&M12 and EXO PMO , compared to CP05-PMO, PMO, and mdx controls, whereas there was no change in the concentrations of alkaline phosphatase (ALP) (Fig. 8A ), blood urea nitrogen (BUN), and creatinine (Crea) (Fig. 8B) , and histology revealed no evidence of liver or renal toxicity (Fig. 8C) . Examination of inflammation revealed no alteration on inflammatory conditions in the kidney, liver, and muscle from mdx mice treated with EXO PMO&M12 or EXO PMO compared to CP05-PMO, PMO, and mdx controls (Fig. 8, D and E) , suggesting that CP05-exosome complexes do not result in any detectable toxicity. Together, these findings demonstrate that CP05 enables safe and targeted delivery of therapeutic cargo via exosomes and is a valuable tool for exosome engineering.
DISCUSSION
Here, we identified an anchor peptide specific for the second extra vesicular loop of CD63. This peptide can bind to CD63-expressing exosomes irrespective of origin, including human circulatory exosomes. This peptide enables efficient modification of the same exosome with different moieties and thus allows for specific targeting of different therapeutic cargoes to desired tissues, making CP05-modified exosomes worth further exploration as safe and efficient delivery vehicles for different types of therapeutics.
CP05 also presents the possibility of capturing and using patientderived exosomes to deliver therapeutic cargoes to target organs. Our study provides evidence that this exosomal anchor peptide can anchor various types of homing moieties, which could be used to potentially paint antigenic epitopes and immunoadjuvant molecules on exosomes. Exosomes have been considered as a natural alternative to liposomes as delivery systems because of their low/no immunogenicity, evasion from phagocytosis by monocytes and macrophages, and enhanced retention in the circulation (25, 30) . Patient exosomes captured from serum with CP05 could potentially be used to modify exosomes for therapeutic purposes, particularly to avoid immunological reactions that could be associated with foreign exosomes. This delivery method makes use of the natural uptake of unmodified exosomes by endogenous mechanisms (31) and should translate easily to clinical use. As a proof of concept, therapeutic amounts of dystrophin were achieved with EXO PMO at extremely low doses of PMO and elicited functional rescue in mdx mice without any detectable toxicity, indicating that the exosome is an efficient delivery vehicle for PMO. Beyond peptides and AOs, CP05 can theoretically be used to anchor any moiety on exosomes as long as the moiety can be conjugated to CP05. It is also likely to load other AOs on exosomes, such as 2′-O-methyl phosphorothioate RNA (2′OMe). Therefore, CP05 can be broadly applied to the loading of a large variety of cargoes on exosomes and thus applicable to different diseases. This study demonstrates that efficient oligonucleotide delivery can be achieved with CP05-conjugated exosomes in mice. The ability to mix and match targeting and cargo moieties with ready-made exosomes from different cellular sources gives researchers a tool to rapidly deliver macromolecules into specific tissues to answer specific biological questions. Further use could include a variety of therapeutic, targeting peptide, and oligonucleotide combinations, such as targeting neurodegenerative diseases with therapeutic PMO and neuron-specific RVG peptide conjugated via CP05 on exosomes.
This study also demonstrates that exosomes can be harvested from human serum for diagnostics using CP05, as indicated by the detection of specific cancer biomarkers from cancer patient serum. CP05 is a short peptide that would be cheaper to produce and easier to conjugate than monoclonal antibodies currently used to isolate exosomes specifically. Thus, CP05 would be an attractive prospect to develop for clinical diagnostics.
In conclusion, this study demonstrates a proof of concept for the direct, effective modification, cargo loading, and capture of exosomes via an exosomal anchor peptide, which can simplify the procedure for genetic engineering and cargo loading of exosomes. This technology should be of general utility for research and therapeutic applications in other disease models.
MATERIALS AND METHODS

Study design
Here, we designed a study to (i) identify an exosomal peptide via phage display screening, (ii) validate the binding affinity and specificity, (iii) test the modification efficiency with tissue-targeting peptides, (iv) evaluate efficiency of circulatory exosome capture, and (v) treat dystrophin-deficient mdx mice with exosomes modified with both muscle-targeting peptide and exon-skipping oligonucleotides. For functional, histological, and molecular evaluations, the number of animals per group was minimized to three to six mice, as specified in the figure legends. Numbers were determined by the investigator on the basis of previous experimental experience. All experimental procedures were carried out in the animal unit (Tianjin Medical University, Tianjin, China) according to procedures authorized by the institutional ethical committee (permit no. SYXK 2009-0001).
Cell culture
Murine C2C12 cells (mouse myoblasts) were maintained in house and cultured as previously reported (32) . Briefly, cells were grown at 37°C in 5% CO 2 in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum (FBS) and 1% penicillin and streptomycin. Mouse Hepa1-6 was purchased from Boster Biological Technology Ltd. and cultured in DMEM medium with 2 mM glutamine and 10% FBS, as per the manufacturer's instructions. Human myoblasts were provided by J. Morgan (University College London Institute of Child Health, London, UK) and were cultured in skeletal muscle cell growth medium (PromoCell) supplemented with 1.5% GlutaMAX (Gibco), 20% FBS, and 1% penicillin and streptomycin. Myotubes were obtained from confluent C2C12 or human myoblasts seeded in gelatin-coated 12-well plates after 3 days of serum deprivation at 37°C under a 5% CO 2 atmosphere in DMEM with 5% horse serum (HyClone). Primary human liver (7702) and human HeLa cells were provided by N. Zhang (Tianjin Medical University, Tianjin, China) and cultured as previously described (33, 34) .
Animals and injections
Six-to 8-week-old mdx (Dmd mdx ; dystrophin-deficient) and immunodeficient nude mice were purchased from the Jackson Laboratory and used in all experiments (three mice in each of the test and control groups, unless otherwise specified). C57BL/6 mice were used as wild-type controls and also for establishing subcutaneous HCC models (three mice in each of the test and control groups). Briefly, Hepa1-6 cells were digested with 0.25% trypsin in the logarithmic phase. Hepa1-6 (3 × 10 6 ) cells were suspended in 50 l of phosphate-buffered saline (PBS) and subcutaneously injected into left axilla of C57BL/6 mice using a 1-ml syringe.
For local intramuscular injection, 1 g of PMO, CP05-PMO, or EXO PMO was dissolved in saline. For the colocalization study, 2 g of PMO was used with DiR-labeled exosomes (2 g) and injected into tibialis anterior muscles of adult mdx mice. For intravenous injections, various amounts of PMO, CP05-PMO, EXO PMO , or EXO M12&PMO in 100 l of saline solution were injected into tail veins of mdx mice at 12.5 mg of PMO per kilogram per week (1:1 ratio for PMO and EXO) for 1 or 3 weeks. Mice were sacrificed by terminal anesthesia, followed by perfusion at desired time points, and muscles and other tissues were snap-frozen in liquid nitrogen-cooled isopentane and stored at −80°C.
Peptide, PMO, and PMO-peptide conjugates
The PMO sequence against the boundary sequences of exon and intron 23 of murine Dmd gene was 5′-ggccaaacctcggcttacctgaaat-3′ and designated as 25-nucleotide oligomer PMO (table S1) (16) . PMOs were synthesized by Gene Tools LLC. Conjugations of CP05 with PMO were synthesized by a stable amide linker. All conjugates are provided by H.M.M. (Oregon State University, Corvallis, OR, USA). Fluorescence-labeled and chimeric peptides of M12-CP05, RVG-CP05, SP94-CP05, and NP41-CP05 were synthesized and provided with >95% purity by Chinapeptide Co. Ltd. Detailed AO and peptide sequences are shown in table S1.
In vitro biopanning
The Ph.D.-12 phage display library (New England BioLabs) was used for in vitro biopanning experiments. Purified CD63 protein fragment containing the second extracellular loop (LEL) (Life Technologies) was used for in vitro selection. Briefly, 20 g of CD63 LEL purified protein was precoated onto Corning 96-well White Polystyrene Medium Bind Stripwell microplates (Corning) overnight, and unbound protein was removed and washed with PBS, followed by blocking with 5% bovine serum albumin (BSA) in PBS. Phages (1 ×  10 12 plaque-forming units) were incubated with CD63 LEL purified protein for 2 hours, and unbound phages were removed by washing with PBS solution for three times. The bound phages were recovered with glycine-HCl buffer (pH 2.2), followed by neutralization with tris-HCl buffer (pH 8.8). Recovered phages were titered and amplified for subsequent cycles. This process was repeated twice, and the recovered phage clones' sequences were identified by high-throughput sequencing (Genewiz).
Preparation and purification of exosomes
Cell culture medium was sequentially centrifuged at 1000g for 10 min, followed by 10,000g for 30 min. The supernatant was collected and filtered with a 0.22-m filter (Millex), followed by ultracentrifugation at 100,000g for 1 hour to pellet exosomes. Exosome pellets were washed in a large volume of PBS and recovered by centrifugation at 100,000g for 1 hour. The total protein concentration of exosomes was quantified by the Bradford assay (Sangon Biotech). For human serum exosome isolation, human serum was obtained from healthy volunteers (provided by Tianjin Blood Center, Tianjin, China) and centrifuged at 3000g, 6000g, and 10,000g twice for 30 min each time to remove cell debris. The supernatant was transferred into a fresh tube, filtered with a 0.22-μm filter, and pelleted by ultracentrifugation (Beckman Optima L-100 XP, Beckman Coulter) at 100,000g for 1 hour and further purified by sucrose density gradient centrifugation. Exosomes were layered on a linear sucrose gradient (0.65, 0.85, 1.05, 1.25, 1.45, and 1.65 M sucrose; Sigma-Aldrich). The gradients were centrifuged for 18 hours at 100,000g at 4°C. Six fractions from 0.65 to 1.65 M sucrose gradients were collected and ultracentrifuged at 100,000g for 1 hour at 4°C to pellet exosomes. The exosome pellets were dissolved in PBS, and the total protein concentration of exosomes was quantified by the Bradford assay (Sangon Biotech).
Characterization of exosomes
Exosomal size distribution was measured by Nano Particle Tracking and Zeta potential distribution analyzer (ParticleMetrix-PMX). Morphology was visualized using a high-resolution transmission electron microscope (Hitachi HT7700). Briefly, the resuspended exosomes were diluted into water (1 g/l) and mixed with an equal volume of 4% paraformaldehyde. Exosomes were adsorbed onto a glowdischarged, carbon-coated formvar film attached to a metal specimen grid. Excess solution was blotted off, and the grid was immersed with a small drop (50 l) of 1% of glutaraldehyde for 5 min, followed by washing with 100 l of distilled water for eight times (2 min each time). Subsequently, the grid was transferred to 50 l of uranyloxalate solution (pH 7.0) for 5 min and then to 50 l of methyl cellulose-uranyl acetate (100 l of 4% uranyl acetate and 900 l of 2% methyl cellulose) for 10 min on ice. The excess solution was blotted off, and the sample was dried and examined in the transmission electron microscope.
Exosome capture from human serum Human serum was obtained from healthy volunteers (n = 10), provided by Tianjin Blood Center (Tianjin, China) or HCC (n = 15) or pancreatic cancer patients (n = 18) (provided by Tianjin Medical University Cancer Institute and Hospital). All patients provided written informed consent for the sample collection. This study was conducted in accordance with Declaration of Helsinki and was approved by the Tianjin Medical University Cancer Institute and Hospital Ethics Committee. Serum was centrifuged to remove cell debris, as described above, followed by diafiltration with a 0.22-m filter. Histagged CP05 (200 g/ml) was incubated with nickel Dynabeads (20 l; Solarbio) at room temperature for 2 hours to allow CP05 to bind to beads, followed by washing with washing buffer [20 mM Na 2 HPO 4 , 500 mM NaCl, and 75 mM imidazole (pH 7.4)] three times to remove unbound peptides. Subsequently, recovered beads were added into the precentrifuged serum (200 l) and incubated for 30 min at 4°C under rotation. After incubation, the supernatant was discarded, the beads were washed three times with washing buffer, and exosomes were eluted with elution buffer [20 mM Na 2 HPO 4 , 500 mM NaCl, and 500 mM imidazole (pH 7.4)]. Captured exosomes were used for TEM, size distribution, and Western blot analysis, as described above. Rabbit polyclonal AFP (1:1000; Abcam) and GPC1 (1:1000; Abcam) antibodies were used to examine the expression of AFP and GPC1 in captured exosomes.
Fluorescence microscopy and flow cytometry
To measure the binding affinity of candidate peptides on exosomes, exosomes (30 g) derived from C2C12 myotubes (unless otherwise specified) were preincubated with rhodamine-labeled CP05, CP06, or CP07 peptide (30 g) overnight at 4°C, followed by washing with PBS for five times in 2-ml ultracentrifuge tubes and filtration with 100-kDa diafiltration tube (Millipore) to remove unbound peptides. Subsequently, peptide-exosome complexes (30 g) were incubated with 4-mm aldehyde/sulfate latex beads (Invitrogen) for 15 min at room temperature under rotation and washed with PBS for three times. Recovered beads were observed with a conventional fluorescence microscope (FV1000, Olympus) or subjected to flow cytometry (FACSCalibur, BD). Uncoated beads were used as negative controls for gating. To validate flow cytometry (FACSCalibur, BD) for direct measurement of exosomes, we first tested the following: (i) the buffer used to dissolve exosomes to evaluate the buffer background noise; (ii) the resuspended pellet from a 100,000g ultracentrifugation of cell culture medium to evaluate the background noise; and (iii) 100-nm and 200-nm beads (polystyrene sphere, Ruixibio) to define the target populations. Reference beads were used to set the voltages and the thresholds for measurement, as well as provide reference for gating of beads in the forward-scatter/side-scatter channels. To examine whether flow cytometry can be used to characterize individual exosomes, we labeled exosomes with Pkh67 (Sigma-Aldrich) or DiR (Life Technologies) as per the manufacturer's instruction and subjected to flow cytometry individually or together. To measure the percentage of CD63-positive exosomes in total exosomes, DiR-labeled exosomes (5 g) were incubated with phycoerythrin (PE)-Cy7-labeled antimouse CD63 antibody (1:20; eBioscience) or PE-Cy7-labeled rat immunoglobulin G2a (IgG2a) isotype control (1:20; eBioscience) in 4% BSA for 30 min at 4°C, followed by 1:10 dilution with PBS, and were analyzed with flow cytometry (FACSCalibur, BD). To quantify the modification efficiency of CP05, tissue-targeting peptides, and PMOs on exosomes, rhodamine-labeled peptides (20 g) or Lissaminelabeled PMOs (20 g) were incubated with DiR-labeled exosomes (5 g) at 4°C for 6 hours and washed with PBS for five times in 2-ml ultracentrifuge tubes, followed by filtration with diafiltration tubes (Millipore) to remove unbound peptides or PMOs before flow cytometry. For dual modification of exosomes, FITC-labeled NP41-CP05 (30 g) and rhodamine-labeled M12 (30 g) peptides were incubated with 30 g of exosomes at 4°C for 6 hours individually or together and washed with PBS and filtered to remove unbound peptides before flow cytometry, as described above.
Coimmunoprecipitation
Cell or exosome pellets were lysed with RIPA lysis buffer (Sangon Biotech) containing protease inhibitor cocktails (Roche). Cell or exosome lysates were spun at 14,000g for 30 min, followed by 50,000g for 30 min, and the protein concentration was measured with Bradford assay (Sigma-Aldrich). For the coimmunoprecipitation of cell lysates, to avoid the nonspecific binding with beads, total protein (1 mg) was preincubated with 150 g of protein A-Sepharose beads (Sigma-Aldrich) for 15 min at 4°C, followed by centrifugation at 1500g for 15 min, and the supernatant was recovered. Polyclonal rabbit anti-CD63 or control anti-IgG antibody (1 g) was co-incubated with protein A-Sepharose beads (150 g) and the supernatant overnight at 4°C. Subsequently, the beads were washed three times with lysis buffer and harvested, followed by incubation with His-tagged peptides for 2 hours. To remove free peptides, the beads were washed with PBS with Tween 20 for three times. The disassociated complex (20 l) was used for Western blot with His-tag and/or CD63 antibodies (Santa Cruz Biotechnology) at a dilution of 1:1000. For exosome immunoprecipitation, nickel Dynabeads (Solarbio) were preincubated with 100 g of His-tagged CP05, CP07, or scrambled CP05 for 2 hours at 4°C. After incubation, beads were washed with washing buffer [20 mM Na 2 HPO 4 , 500 mM NaCl, and 75 mM imidazole (pH 7.4)] for three times to remove unbound peptides. Recovered beads were incubated with 200 g of exosome lysates for 30 min at 4°C. After incubation, the supernatant was discarded, beads were washed three times with washing buffer, and exosome lysates were eluted with elution buffer [20 mM Na 2 HPO 4 , 500 mM NaCl, and 500 mM imidazole (pH 7. 
Fluorescence resonance energy transfer assay
FRET assay was used to examine the simultaneous binding of two different peptides on the same exosome. FITC-labeled NP41 (10 g) (Ex, 488 nm; Em, 520 nm) and rhodamine-labeled RVG (10 g) (Ex, 525 nm; Em, 625 nm) were incubated with exosomes (10 g) individually or together and washed with PBS for three times before measurement with a plate reader (EnSpire Multimode Plate Reader, PerkinElmer).
Serum stability assay CP05 peptides (1 mM) were incubated in PBS containing 20% mouse serum at 37°C. Aliquots of 20 l were taken at 0, 15, 30, 60, 120, and 360 min and diluted with 10 l of 10% trichloroacetic acid to precipitate serum protein. The samples were mixed and kept at −20°C for 30 min to allow for complete precipitation. The precipitated serum proteins were removed by centrifugation (13,000 rpm, 5 min), and the supernatant was analyzed by LC-MS.
Tissue distribution
To examine the biodistribution of CP05-modified and homing moiety-CP05-modified exosomes in immunodeficient nude mice and wildtype C57BL/6 mice, DiR-labeled exosomes and AF680-labeled peptides were used. Briefly, exosomes (EXO), CP05-modified exosomes (EXO CP05 ), and M12-CP05-painted exosomes (EXO M12 ), RVG-CP05-painted exosomes (EXO RVG ), and SP94-CP05-painted exosomes (EXO SP94 ) (30 g) were administered intravenously into immunodeficient nude mice, C57BL/6 mice, or mice bearing subcutaneous HCC for a single injection, respectively. For human serum-derived exosomes, Pkh67-labeled exosomes (30 g) were used for animal imaging studies. Perfusion was performed 2 hours after injection with 50 ml of cold PBS to wash out exosomes in circulation. Bodywide muscles, liver, tumor, kidney, and spleen were harvested for imaging with IVIS spectrum (PerkinElmer).
RNA extraction and nested RT-PCR analysis
Sections were cut, collected, and homogenized in TRIzol reagent (Invitrogen). Total RNA was then extracted, and 200 ng of RNA template was used for a RT-PCR with a OneStep RT-PCR kit (Qiagen). The primer sequences for the initial RT-PCR were 5′-CAGAAT-TCTGCCAATTGCTGAG-3′ (exon 20 F0) and 5′-TTCTTCAGCTT-TTGTGTCATCC-3′ (exon 26 R0) for reverse transcription from mRNA and amplification of complementary DNA from exons 20 to 26. The cycling conditions were 95°C for 1 min, 55°C for 1 min, and 72°C for 2 min for 25 cycles. The primer sequences for the second rounds were 5′-CCCAGTCTACCACCCTATCAGAGC-3′ (exon 20 F1) and 5′-CCTGCCTTTAAGGCTTCCTT-3′ (exon 24 R1). The cycling conditions were 95°C for 1 min, 57°C for 1 min, and 72°C for 1 min for 25 cycles. Products were examined by electrophoresis on a 2% agarose gel. RNA extracted from tibialis anterior muscles of C57BL/6 and mdx mice was used as normal and positive controls. The quantification of full-length and skipped RT-PCR bands is based on densitometry of gel images and analyzed with ImageJ software (https://imagej.nih.gov/ij/).
Protein extraction and Western blot
Exosome pellets were lysed with lysis buffer and subjected to 10% SDS-polyacrylamide gel electrophoresis gels and transferred to a polyvinylidene difluoride membrane. Polyclonal rabbit anti-Alix (1:200; Santa Cruz Biotechnology), anti-CD63 (1:200; Santa Cruz Biotechnology), and anti-CD9 (1:1000; Abcam) antibodies and mouse monoclonal Tsg101 (1:200; Santa Cruz Biotechnology) were used as primary antibodies to confirm the presence of exosomes. Cytochrome c (1:1000; Santa Cruz Biotechnology) was used as the primary antibody to examine the possible contamination of organelles. For dystrophin expression, protein extraction and Western blot were carried out as previously described (35) . Various amounts of protein from wild-type C57BL/6 mice were used as positive controls, and corresponding amounts of protein from muscles of treated or untreated mdx mice were loaded onto SDS-polyacrylamide gel electrophoresis gels (4% stacking and 6% resolving). The membrane was then washed and blocked with 5% skimmed milk and probed overnight with DYS1 (mouse monoclonal; 1:200; Abcam) for the detection of dystrophin protein and -actinin (mouse monoclonal; 1:5000; Sigma-Aldrich) as a loading control. The bound primary antibody was detected by peroxidase-conjugated goat anti-mouse IgG (Sigma-Aldrich) and the ECL Western blot analysis system (Millipore). The intensity of the bands obtained from treated mdx muscles was measured by ImageJ software. The dystrophin/-actinin ratios of treated samples were normalized to the average C57BL/6 dystrophin/-actinin ratios (from serial dilutions). Each experiment was performed at least three times (at least three animals).
Immunohistochemistry and histology
Sections of 8 m were cut from tibialis anterior, quadriceps, gastrocnemius, triceps, abdominal and diaphragm, and cardiac muscles. Sections were then examined for dystrophin expression with a rabbit polyclonal antibody 2166 against the dystrophin C-terminal region (the antibody was provided by K. Davies, Department of Physiology, Anatomy and Genetics, University of Oxford). Polyclonal antibodies were detected by goat anti-rabbit IgG Alexa Fluor 594 (Invitrogen). For the colocalization study, sections were examined with a confocal fluorescence microscope (FV1000, Olympus). The serial sections were also stained with a panel of polyclonal and monoclonal antibodies for the detection of DAPC components. Rabbit polyclonal antibody to neuronal nitric oxide synthase (1:50) and mouse monoclonal antibodies to -dystroglycan and -sarcoglycan were used according to the manufacturer's instructions (1:200; Novocastra). The M.O.M. blocking kit (Vector Laboratories) was applied for the immunostaining of the DAPC. To examine the presence of CD3 T lymphocytes and macrophages in tissues from treated mdx mice or controls, mouse tissues were fixed in Bouin's solution (Sigma-Aldrich) and embedded with paraffin. CD3 + T lymphocytes or CD68 + macrophages were stained with rabbit-anti-mouse polyclonal antibodies CD3 (1:200; Abcam) or CD68 (1:500; Abcam) and detected by goatanti-rabbit secondary antibody. Routine H&E staining was used to examine the overall liver and kidney morphology and assess the level of infiltrating mononuclear cells.
Serum enzyme measurements
Mouse blood was taken immediately after cervical dislocation and centrifuged at 1500 rpm for 3 min. Serum was separated and stored at −80°C. Analysis of levels of serum CK, AST, ALT, ALP, BUN, and Crea was performed by the clinical laboratory (Tianjin Metabolic Disease Hospital, Tianjin Medical University, Tianjin, China).
Functional grip strength
Treated and control mice were tested using a commercial grip strength monitor (Chatillon). Briefly, each mouse was held 2 cm from the base of the tail, allowed to grip a protruding metal triangle bar attached to the apparatus with their forepaws, and pulled gently until they released their grip. The force exerted was recorded, and five sequential tests were carried out for each mouse, averaged at 30 s apart. Subsequently, the readings for force recovery were normalized by the body weight.
Statistical analysis
All data are means ± SEM. Statistical differences between treatment and control groups were evaluated by SigmaStat (Systat Software). Both parametric and nonparametric analyses were applied, in which the Mann-Whitney rank sum test (Mann-Whitney U test) was used for samples on a non-normal distribution, whereas a two-tailed t test was performed for samples with a normal distribution, respectively.
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